Table 3.
Drug resistance patterns of 66 MDR-, pre-XDR- and XDR-TB clinical isolates from a major hospital in Guizhou Province of China
| Drug resistance patterns | New cases (n=11)
|
Previously treated cases (n=55)
|
Total cases (n=66)
|
|||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
|
| ||||||
| MDR (no. of anti-TB drugs) | ||||||
| RIF, INH (2) | 3 | 27.3 | 6 | 10.9 | 9 | 13.6 |
| RIF, INH, EMB (3) | 1 | 9.1 | 7 | 12.7 | 8 | 12.1 |
| RIF, INH, STR (3) | 1 | 9.1 | 8 | 14.6 | 9 | 13.6 |
| RIF, INH, EMB, STR (4) | 3 | 27.3 | 13 | 23.6 | 16 | 24.3 |
| Subtotal | 8 | 72.7 | 34 | 61.8 | 42 | 63.6 |
| Pre-XDR (no. of anti-TB drugs) | ||||||
| RIF, INH, EMB, LFX (4) | 0 | 0.0 | 1 | 1.8 | 1 | 1.5 |
| RIF, INH, EMB, MOX (4) | 0 | 0.0 | 1 | 1.8 | 1 | 1.5 |
| RIF, INH, LFX, MOX (4) | 1 | 9.1 | 0 | 0.0 | 1 | 1.5 |
| RIF, INH, EMB, LFX, MOX (5) | 0 | 0.0 | 1 | 1.8 | 1 | 1.5 |
| RIF, INH, EMB, STR, LFX (5) | 1 | 9.1 | 1 | 1.8 | 2 | 3.1 |
| RIF, INH, EMB, STR, MOX (5) | 0 | 0.0 | 1 | 1.8 | 1 | 1.5 |
| RIF, INH, STR, AMK, KAN (5) | 0 | 0.0 | 1 | 1.8 | 1 | 1.5 |
| RIF, INH, EMB, AMK, CAP, KAN (6) | 0 | 0.0 | 1 | 1.8 | 1 | 1.5 |
| RIF, INH, EMB, STR, GFX, LFX (6) | 0 | 0.0 | 2 | 3.7 | 2 | 3.1 |
| RIF, INH, EMB, STR, AMK, CAP, KAN (7) | 0 | 0.0 | 1 | 1.8 | 1 | 1.5 |
| RIF, INH, EMB, STR, GFX, LFX, MOX (7) | 0 | 0.0 | 4 | 7.4 | 4 | 6.1 |
| Subtotal | 2 | 18.2 | 14 | 25.5 | 16 | 24.3 |
| XDR (no. of anti-TB drugs) | ||||||
| RIF, INH, STR, LFX, KAN (5) | 0 | 0.0 | 1 | 1.8 | 1 | 1.5 |
| RIF, INH, STR, LFX, MOX, AMK (6) | 0 | 0.0 | 1 | 1.8 | 1 | 1.5 |
| RIF, INH, EMB, LFX, MOX, AMK, CAP, KAN (8) | 0 | 0.0 | 1 | 1.8 | 1 | 1.5 |
| RIF, INH, EMB, STR, GFX, LFX, MOX, AMK (8) | 0 | 0.0 | 3 | 5.5 | 3 | 4.5 |
| RIF, INH, EMB, STR, GFX, LFX, MOX, AMK, CAP (9) | 1 | 9.1 | 1 | 1.8 | 1 | 1.5 |
| Subtotal | 1 | 9.1 | 7 | 12.7 | 8 | 12.1 |
| Total | 11 | 100.0 | 55 | 100.0 | 66 | 100.0 |
Abbreviations: AMK, amikacin; CAP, capreomycin; EMB, ethambutol; GFX, gatifloxacin; INH, isoniazid; KAN, kanamycin; LFX, levofloxacin; MDR, multidrug resistant; MOX, moxifloxacin; pre-XDR, MDR with additional resistance to a fluoroquinolone or a second-line injectable drug; RIF, rifampicin; STR, streptomycin; TB, tuberculosis; XDR, extensively drug resistant.